Verve Therapeutics Cash Flow Statement

Financials in millions IDR. Fiscal year is January - December.

Millions IDR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	111,861	102,480	90,335
Depreciation & Amortization	114,047	3,550	105,184
Other Operating Activities	-30,327	120,004	-46,545
Operating Cash Flow	195,582	226,034	148,974
Operating Cash Flow Growth	-13.47%	51.73%	-
Capital Expenditures	-196,199	-96,668	-151,646
Sale of Property, Plant & Equipment	13,430	15,116	18,272
Sale (Purchase) of Intangibles	-	-49.2	-
Sale (Purchase) of Real Estate	-12,095	-37,166	-
Other Investing Activities	-	-410.22	-
Investing Cash Flow	-194,863	-119,178	-133,375
Long-Term Debt Issued	97,000	20,000	90,000
Long-Term Debt Repaid	-50,483	-65,280	-64,113
Net Debt Issued (Repaid)	46,517	-45,280	25,887
Common Dividends Paid	-99,995	-30,011	-25,299
Other Financing Activities	-	4	1
Financing Cash Flow	-53,478	-75,287	588.64
Net Cash Flow	-52,759	31,569	16,187
Free Cash Flow	-616.86	129,367	-2,673
Free Cash Flow Margin	-0.06%	13.38%	-0.33%
Free Cash Flow Per Share	-6.55	4090.78	-84.52
Cash Interest Paid	14,402	14,393	13,978
Cash Income Tax Paid	35,009	32,703	31,307
Levered Free Cash Flow	-18,230	2,474	-
Unlevered Free Cash Flow	-9,228	11,469	-
Change in Net Working Capital	16,963	-22,421	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.